Although in vivo studies are required to clarify the role of anti-hnRNP A1-M9 antibodies in the pathogenesis of neurodegeneration in MS, an important link is made because (1) the monoclonal antibodies used in this study overlap the human immunodominant epitope of hnRNP A1–M9 recognized by IgG isolated from MS patients, (2) the SPG data supports previous data shown in vitro and in neurons isolated from MS brains and (3) the SPGs are clinically relevant targets [12,24]. This evidence concerns the gene EIF3K and myeloid sarcoma.